Compare INGN & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INGN | MDWD |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.6M | 193.3M |
| IPO Year | 2013 | 2013 |
| Metric | INGN | MDWD |
|---|---|---|
| Price | $6.27 | $16.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $11.00 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 224.0K | 68.4K |
| Earning Date | 05-06-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $348,668,000.00 | N/A |
| Revenue This Year | $7.92 | $48.88 |
| Revenue Next Year | $7.86 | $35.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.86 | N/A |
| 52 Week Low | $5.34 | $14.14 |
| 52 Week High | $9.13 | $22.51 |
| Indicator | INGN | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 51.57 | 46.12 |
| Support Level | $6.26 | N/A |
| Resistance Level | $6.83 | $18.71 |
| Average True Range (ATR) | 0.25 | 0.64 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 51.55 | 54.55 |
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.